Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OM-85-IN (OM Pharma)
- Development stage
- Unknown
- Lead developer
- OM Pharma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
OM-85-IN is an investigational intranasal formulation of OM-85, a standardized bacterial lysate developed by OM Pharma. OM-85 is composed of lyophilized alkaline extracts from 21 strains of 8 common respiratory bacterial species, including *Haemophilus influenzae*, *Streptococcus pneumoniae*, and *Staphylococcus aureus*. The drug acts as an immunomodulator by activating innate immune cells via Toll-like receptors (TLRs), particularly TLR2, TLR4, TLR7, and TLR9. This activation leads to the maturation of dendritic cells and a shift in the adaptive immune response from a pro-allergic Th2 profile toward a protective Th1 profile, while also enhancing regulatory T cell (Treg) activity. While the oral version of OM-85 (marketed as Broncho-Vaxom) is established for preventing recurrent respiratory infections, OM-85-IN is specifically being evaluated for its safety and efficacy in treating and preventing allergic asthma by targeting the airway mucosa directly.
- Other names
- bacterial lysate OM-85Broncho-Vaxom
02
Targets
LY96 (Myeloid differentiation factor 2)MYD88 (Myeloid differentiation primary response protein MyD88)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)TLR7 (Toll-like receptor 7)TLR9 (Toll-like receptor 9)TRIF (TIR-domain-containing adapter-inducing interferon-beta)
Beyond the preview
Go deeper on OM-85-IN (OM Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OM-85-IN (OM Pharma).